You are here

Article Text

Article menu
Download PDFPDF
Letter
Dimethyl fumarate for COVID-19
  1. Yashdeep Singh Pathania
  1. Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, 342005, India
  1. Correspondence to Dr Yashdeep Singh Pathania, Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, 342005, India; yashdeepsinghpathania{at}gmail.com

https://doi.org/10.1136/bmjspcare-2021-003250

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the editor,

    The menace of COVID-19 pandemic has entered into the second year, and still it is expanding, evading every possible medical therapy being offered. There has been no specific antiviral therapy for SARS CoV-2 discovered to date. It has been found that COVID-19 induces immune dysregulation, hyperinflammation and oxidative stress (cytokine storm), which leads to patient morbidity and even mortality. The alleviation of cytokine storm is a logical approach to decrease the mortality. Dexamethasone (corticosteroid) has been successfully used in the treatment of COVID-19.1 Dimethyl fumarate (DMF) has comparable immunosuppressive properties like corticosteroids and has shown effectiveness in COVID-19. …

    View Full Text

    Footnotes

    • Contributors Author (YSP) prepared and finalised the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.